Related Experiment Video
Updated: Jun 9, 2026
08:38
Targeted DNA Methylation Analysis by Next-generation Sequencing
Published on: February 24, 2015
Reduction of next-generation sequencing files for efficient pharmacogenotype extraction
Hargoon N Kaur1, Reynold C Ly2,3,4, Steven M Bray5
1Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Pharmacogenomics
|June 8, 2026
Summary
Aldy accurately extracts pharmacogenotypes from reduced Binary Alignment/Map (BAM) files, significantly cutting storage needs. This method maintains genotype accuracy while saving over 1,000 times the computational storage resources.
Area of Science:
- Genomics
- Bioinformatics
- Pharmacogenomics
Background:
- Comprehensive pharmacogenotype extraction relies on Binary Alignment/Map (BAM) files, demanding substantial storage.
- Aldy is a validated pharmacogenotyping tool capable of genotype extraction from targeted DNA sequencing.
Purpose of the Study:
- To evaluate Aldy's accuracy in extracting genotypes for 14 major pharmacogenes from reduced clinical exome (ES) and genome (GS) sequencing BAM files.
- To quantify the computational storage savings achieved by reducing BAM files to pharmacogene regions.
Main Methods:
- Germline ES (n=160) and GS (n=94) BAM files were processed to retain only pharmacogene regions.
- Aldy was employed to extract genotypes from both original and reduced BAM files for comparative analysis of accuracy and file size.
Main Results:
- Genotype calls from reduced ES and GS BAM files were fully concordant with those from the original, larger files.
- Reducing BAM files to pharmacogene regions resulted in a >1,000-fold decrease in file size, from ~9.7 GB to 7.6 MB for ES and ~107 GB to 51.8 MB for GS.
Conclusions:
- Aldy accurately extracts pharmacogenotypes from reduced BAM files.
- This approach significantly reduces computational storage requirements for pharmacogenomic analyses.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
03:00Next-generation Sequencing
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...